Project Grant DP2AI200977
- The National Institute of Allergy and Infectious Diseases awarded $765,496 to the University of California, Davis on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop recombinant enhanced antiviral restrictors (REAVRs) that broadly inhibit known and emerging viruses to control or prevent vector-borne and zoonotic viral diseases. The project will generate and optimize REAVR proteins by combining virus-sensing domains with effector domains from...
- The National Institute of Allergy and Infectious Diseases awarded the Connecticut Agricultural Experimental Station $322,096 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify biological drivers of Aedes aegypti vector competence for dengue, Zika, chikungunya, and yellow fever viruses. The research systematically evaluates the relative contributions of host genetics, viral genotype, and microbiome composition to vector competence variability...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,500 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with a completion date of June 30, 2027. This award funds investigator-initiated biomedical research examining the sequence-specific determinants and impacts of NS2 (nonstructural protein 2) interactions with the Influenza A Virus...
- The National Institute of Allergy and Infectious Diseases awarded New Mexico State University $146,671 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2026, for a project grant (R16AI201108) investigating the link between immunometabolism and epigenetics in the malaria vector mosquito Anopheles stephensi. The project employs a multi-omics approach integrating metabolomic, epigenomic, and transcriptomic data to establish mechanistic linkages between...
- The National Institute of Allergy and Infectious Diseases awarded $431,750 to the University of California Irvine on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI199644). The award funds development and validation of a hydro-meteorological malaria model designed to improve forecasts of malaria risk in Africa and to inform tailored vector control strategies adapted to varying environmental and epidemiological...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $273,337 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of persistent sodium currents in modulating mosquito sensory behavior and spatial repellency to transfluthrin, a volatile pyrethroid insecticide. The research focuses on understanding how transfluthrin-based spatial emanators—recommended by the World Health Organization for malaria...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify conserved antiviral host factors that restrict arbovirus replication across insect and mammalian hosts. The award funds development of an arbovirus rescue assay that screens viral immune evasion proteins (IEPs) encoded by mammalian viruses for their ability to sensitize...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $667,643 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a malaria intelligence system and mobile decision-support application for malaria prevention and control in Kenya. The project addresses insecticide-resistant mosquito populations and outdoor biting behavior that have emerged from widespread use of long-lasting insecticide-treated...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $120,312 to the University of California, Berkeley on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into adenosine deaminases acting on RNA (ADARs), enzymes that edit RNA to regulate gene expression and immune responses. The research aims to identify viral and host...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $192,500 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of enteroendocrine cells in West Nile Virus replication and transmission in Culex tarsalis mosquitoes. The research comprises two aims: Aim 1 will use dissociated midgut cells from colonized mosquitoes infected with barcoded WNV, flow cytometry, and sequencing to quantify the...
The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $480,000 on September 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular basis for arboviral fitness in vector and reservoir hosts. The research examines how arboviruses replicate across evolutionarily distant hosts—insects and vertebrates—despite showing high specificity in their transmission cycles. Using alphaviruses as a model system, the project aims to identify and characterize cell surface receptors that mediate entry into Aedes mosquito cells and to identify viral determinants that drive entry into Aedes cells, particularly for Aedes-transmitted alphaviruses compared to other mosquito-transmitted species. The work will employ insect-specific alphaviruses as a platform to understand the genetic determinants of dual-host range exhibited by pathogenic alphaviruses, focusing on the molecular basis of host specificity and adaptation across the arthropod-vertebrate divide. Performance occurs in La Jolla, California. The project runs from the award date through August 31, 2031. This is a Project Grant assistance type under the program supporting biomedical research and research training in infectious diseases and related areas at public and private nonprofit institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $480.0k | 8/31/26 |